臺灣博碩士論文加值系統

實驗室過去合成了furo[2,3-b]quinoline及furo[3,2-c]quinoline衍生物，其中CIL-102被視為這系列衍生物中的指標藥物，作用機轉為微管抑制劑，但此類化合物共同的缺點有低水溶解度、選擇性不佳以及生物可利用率低的缺點，所以我們針對此類化合物進行結構的修飾，期望可以改善原有的缺點。
實驗數據顯示CIL-102會抑制PC-3、A549、MCF-7以及M-10細胞株，其IC50值分別為2.69, 0.61, 0.31 以及0.95 μM，這數據顯示此化合物對於癌細胞與正常細胞之間不具有選擇性。此實驗中以4-anilinofuro[2,3-b]quinoline作為主架構，在橋鏈的氮上置入烷基進行修飾，合成一系列的衍生物。將此系列衍生物進行體外抑制癌細胞增生的活性評估後，發現化合物N-(4-acetylphenyl)-N- (furo[2,3-b]quinolin-4-yl)methylamine (12a)具有很好的抑制活性及選擇性，針對PC-3 (前列腺癌細胞)其IC50值為0.22 μM。
第二部分實驗中，嘗試以4-anilinofuro[3,2-c]quinoline作為主架構，嘗試置入高親水性的aminoalkyl基團進行修飾，希望藉由提高水溶解度特性，進而提升其生物可利用率。

Certain furo[2,3-b]quinoline and furo[3,2-c]quinoline derivatives have been synthesized and evaluated for their antiproliferative activities. Among them, CIL-102 was found to be the most potent. However, it exhibited general cytotoxicity to most of cancers and normal cells. In addition, it displayed other drawbacks such as low oral availability and poor aqueous solubility. In order to improve these drawbacks, we optimized the chemical structure of CIL-102 to settle these problems.
CIL-102 is active against the growth of PC-3、A549, MCF-7 and M-10 cells with an IC50 value of 2.69, 0.61, 0.31 and 0.95 μM, respectively. Recent reports revealed that replacement of hydrogen on the linker nitrogen of N-(4-methoxyphenyl)-2-methylquinazolin-4-amine with a Me group enhanced over 2000-folds activity of antiproliferation. This dissertation describes synthesis and evaluation of N-alkylated 4-anilinofuro[2,3-b]quinoline derivatives such as CIL-102 with aims to improve anticancer activity and selectivity. Our results indicated that most of the newly synthesized compounds exhibited selective activity against prostate cancer cells. Among them, N-(4-acetylphenyl)- N-(furo[2,3-b]quinolin-4-yl)methylamine (12a) was one of the most potent antiproliferative agents with an IC50 value of 0.22 μM against PC-3 cell growth.
In the second part, we describe the preparation of furo[3,2-c]quinoline derivatives substituted with aminoalkyl hydrophilic groups and structural verification of these newly synthesized compounds.

中文摘要 1
英文摘要 2
壹、緒論 3
貳、4-苯胺&;#21579;喃[2,3-b]&;#21945;?翮l生物的合成 8
一、研究背景及目的 8
二、合成目標 14
三、合成方法、結果與討論15
(一)、逆合成分析15
(二)、實驗結果與討論16
四、目標化合物活性結果與討論 21
五、結論 30
&;#21444;、4-苯胺&;#21579;喃[3,2-c]&;#21945;?翮l生物的合成 32
一、研究背景及目的 32
二、合成目標 38
三、合成方法、結果與討論40
(一)、逆合成分析40
(二)、實驗結果與討論42

肆、合成實驗部分 47
一、溶劑處理過程 47
二、儀器 47
三、試藥 49
四、各化合物的製備 51
伍、參考文獻 51
陸、研究成果目錄 126

1.Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics. CA. Cancer J. Clin., 2014, 64, 9-29.
2.Asmane, I.; C&;#233;raline, J.; Duclos, B.; Rob, L.; Litique, V.; Barth&;#233;l&;#233;my, P.; Bergerat, J. P.; Dufour, P.; Kurtz, J. E. New strategies for medical management of castration-resistant prostate cancer. Oncology, 2011, 80, 1-11.
3.Cookson, M. S.; Roth, B. J.; Dahm, P.; Engstrom, C.; Freedland, S. J.; Hussain, M.; Lin, D. W.; Lowrance, W. T.; Murad, H.; Oh, W. K.; Penson, D. F.; Kibel, A. S. Castration -Resistant Prostate Cancer: AUA Guideline. J. Urol., 2013, 190, 429-438.
4.Lin, M.F., Meng, T.C., Rao, P.S., Chang, C.S., Schonthal, A.H., and Lin, F.F. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J. Biol. Chem., 1998, 273, 5939-5947.
5.Hellerstedt, B. A.; Pienta, K. J. The current state of hormonal therapy for prostate cancer. CA . A Cancer Journal for Clinicians, 2002, 52, 154-179.
6.Williams, J. F.; Muenchen, H. J.; Kamradt, J. M.; Korenchuk, S.; Pienta1, K. J. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: An experimental study. The Prostate, 2000, 44, 275–278.
7.Tannock, I. F.; Wit, R. de; Berry, W. R.; Horti, J.; Pluzanska, A.; Chi, K. N.; Oudard, S.; Th&;#233;odore, C.; James, N. D.; Turesson, I.; Rosenthal, M. A.; Eisenberger, M. A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 2004, 351, 1502-1512.
8.Eisenhauer, E. A.; Vermorken, J. B. The taxoids comparative clinical pharmacology and therapeutic potential. Drugs, 1998, 55, 5-30.
9.Small, E. J.; Schellhammer, P. F.; Higano, C. S.; Redfern, C. H.; Nemunaitis, J. J.; Valone, F. H.; Verjee, S. S.; Jones, L. A.; Hershberg, R. M. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol., 2006, 24, 3089-3094.
10.Kantoff, P. W.; Higano, C. S.; Shore, N. D.; Berger, E. R.; Small, E. J.; Penson, D. F.; Redfern, C. H.; Ferrari, A. C.; Dreicer, R.; Sims, R. B.; Xu, Y.; Frohlich, M. W.; Schellhammer, P. F. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med., 2010, 363, 411-422.
11.Bono, de J. S.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Machiels, J.-P.; Kocak, I.; Gravis, G.; Bodrogi, I.; Mackenzie, M. J; Shen, L.; Roessner, M., Gupta, S.; Sartor, A O. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 2010, 376, 1147-1154.
12.Potter, G. A.; Banie, S. E.; Jarman, M.; Rowlands M. G. Novel steroidal inhibitors of human cytochrome P45017α, (l7α-hydroxylase- Cl7, 20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem., 1995, 38, 2463-2471.
13.Bono, J. S. de; Logothetis, C. J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chi, K. N.; Jones, R. J.; Goodman, O. B.; Saad, F.; Staffurth, J. N.; Mainwaring, P.; Harland, S.; Flaig, T. W.; Hutson, T. E.; Cheng, T.; Patterson, H.; Hainsworth, J. D.; Ryan, C. J.; Sternberg, C. N.; Ellard, S. L.; Fl&;#233;chon, A.; Saleh, M.; Scholz, M.; Efstathiou, E.; Zivi, A.; Bianchini, D.; Loriot, Y.; Chieffo, N.; Kheoh, T.; Haqq, C. M.; Scher, H. I. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med., 2011, 364, 1995-2005.
14.Scher, H. I.; Fizazi, K.; Saad, F.; Taplin, M.-E.; Sternberg, C. N.; Miller, K.; Wit, R. de; Mulders, P.; Chi, K. N.; Shore, N. D.; Armstrong, A. J.; Flaig, T. W.; Fl&;#233;chon, A.; Mainwaring, P.; Fleming, M.; Hainsworth, J. D., Hirmand, M.; Selby, B.; Seely, L.; Bono, J. S. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med., 2012, 367, 1187-1197.
15.Nilsson, S.; Larsen, R. H.; Foss, S. D.; Balteskard, L.; Borch, K. W.; Westlin, J.-E.; Salberg, G.; Bruland, O. S. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res., 2005, 11, 4451-4459.
16.Larsen, R. H.; Henriksen, G.; Bruland, O. S. Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning. US 6635234
17.Atwell, G. J.; Cain, B. F.; Seelye, R. N. Potential antitumor agents. 12. 9-anilinoacridines. J. Med. Chem., 1972, 15, 611-615.
18.Denny, W. A.; Atwell, G. J.; Cain, B. F. Potential antitumor agents. 26. anionic congeners of the 9-anilinoacridines. J. Med. Chem., 1978, 21, 5-10.
19.Cain, B. F.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 28. deoxyribonucleic acid polyintercalating agents. J. Med. Chem., 1978, 21, 658-668.
20.Baguley, B. C.; Denny, W. A.; Atwell, G. J.; Cain, B. F. Potential antitumor agents. 35. quantitative relationships between antitumor (L1210) potency and DNA binding for 4''-(9-acridiny1amino)methane- sulfon-m-anisidide analogues. J. Med. Chem., 1981, 24, 520-525.
21.Su, T.-L.; Chou, T.-C.; Kim, J. Y.; Huang, J.-T.; Ciszewska, G.; Ren, W.-Y.; Otter, G. M.; Sirotnak, F. M.; Watanabe, K. A. 9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships. J. Med. Chem., 1995, 38, 3226-3235.
22.Bacherikov, V. A.; Chou, T.-C.; Dong, H.-J.; Chen, C.-H.; Lin, Y.-W.; Tsai, T.-J.; Su, T.-L. Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation. Bioorg. Med. Chem. Lett., 2004, 14, 4719-4722.
23.Lee, K.-H.; Rice, G. K.; Hall, I. H.; Amarnath, V. Antitumor agents. 86.1,2 synthesis and cytotoxicity of α-methylene-γ-lactone-bearing purines. J. Med. Chem., 1987, 30, 586-588.
24.Wang, T.-C.; Leeb, K.-H.; Chen, Y.-L.; Liou, S.-S.; Tzeng, C.-C. Synthesis and anticancer evaluation of certain γ-aryloxymethyl -α-methylene -γ-phenyl-γ-butyrolactones. Bioorg. Med. Chem. Lett., 1998, 8, 2773-2776.
25.Fang, K.-C.; Chen, Y.-L.; Sheu, J.-Y.; Wang, T.-C.; Tzeng, C.-C. Synthesis, antibacterial, and cytotoxic evaluation of certain 7-substituted norfloxacin derivatives. J. Med. Chem., 2000, 43, 3809-3812.
26.Chen, I-L.; Chen, Y.-L.; Tzeng, C.-C. Synthesis and cytotoxic evaluation of some 4-anilino furo[2,3-b]quinoline derivatives. Helv. Chim. Acta., 2002, 85, 2214-2221.
27.Chen, Y.-L.; Chen, I-L.; Wang, T.-C.; Han, C.-H.; Tzeng, C.-C. Synthesis and anticancer evaluation of certain 4-anilinofuro[2,3- b]quinoline and 4-anilinofuro[3,2-c]quinoline derivatives. Eur. J. Med. Chem., 2005, 40, 928-934.
28.Huang, Y. T.; Huang, D. M.; Guh, J. H.; Chen, I. L.; Tzeng, C. C.; Teng, C. M. CIL-102 interacts with microtubule polymerization and causes mitotic arrest following apoptosis in the human prostate cancer PC-3 cell line. J. Biol. Chem., 2005, 280, 2771-2779.
29.Gireesh, K. K.; Rashid, A.; Chakraborti, S.; Panda, D.; Manna, T. CIL-102 binds to tubulin at colchicine binding site and triggers apoptosis in MCF-7 cells by inducing monopolar and multinucleated cells. Biochem. Pharm., 2012, 84, 633-645.
30.Teng, C.-C.; Kuo, H.-C.; Cheng, H.-C.; Wang, T.-C.; Sze, C.-I The inhibitory effect of CIL-102 on the growth of human astrocytoma cells is mediated by the generation of reactive oxygen species and induction of ERK1/2 MAPK. Toxicol. Appl. Pharmacol., 2012, 263, 73-80.
31.Chen, Y.-W.; Chen, Y.-L.; Tseng, C.-H.; Liang, C.-C.; Yang, C.-N.; Yao, Y.-C.; Lu, P.-J.; Tzeng, C.-C. Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers. J. Med. Chem., 2011, 54, 4446–4461.
32.Muller, C. E. Prodrug approaches for enhancing the bioavailability of drugs with low solubility. Chem. Biodivers., 2009, 6, 2071-2083.
33.Earnshaw, W. C.; Martins, L. M.; Kaufmann, S. H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem., 1999, 68, 383-424.
34.Sirisoma, N.; Pervin, A.; Zhang, H.; Jiang, S.; Willardsen, J. A.; Anderson, M. B.; Mather, G.; Pleiman, C. M.; Kasibhatla, S.; Tseng, B.; Drewe J.; Cai S. X. Discovery of N-(4-methoxyphenyl)-N, 2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration. J. Med. Chem. 2009, 52, 2341–2351.
35.Cerri,A.;Almirante, N.;Barassi,P.;Benicchio,A.;Fedrizzi,G.; Ferrari, P.; Micheletti, R.; Quadri, L.; Ragg, E.; Rossi, R.; Santagostino, M.; Schiavone, A.; Serra, F.; Zappavigna, M. P.; Melloni, P. 17β-O- aminoalkyloximes of 5β-androstane-3β,14β-diol with digitalis-like activity: synthesis, cardiotonic activity, structureactivity relationships, and molecular modeling of the Na＋,K＋-ATPase receptor. J.Med.Chem., 2000, 43, 2332–2349.
36.Barry, M. J. Prostate-specific-antigen testing for early diagnosis of prostate cancer. New England Journal of Medicine., 2001, 344, 1373-1377.
37.Saxena, P.; Trerotola, M.; Wang, T.; Li, J.; Sayeed, A.; Vanoudenhove, J.; Adams, D. S.; Fitzgerald, T. J.; Altieri, D. C.; Languino, L. R. PSA regulates androgen receptor expression in prostate cancer cells. Prostate, 2012, 72, 769-776.
38.Cano, C.; Saravanan, K.; Bailey, C.; Bardos, J.; Curtin, N. J.; Frigerio, M.; Golding, B. T.; Hardcastle, I. R.; Hummersone, M. G.; Menear, K. A.; Newell, D. R.; Richardson, C. J.; Shea, K.; Smith, G. C. M.; Thommes, P.; Ting, A.; Gri&;#64259;n, R. J. 1&;#8209;Substituted (dibenzo[b,d]thiophen-4-yl)-2morpholino&;#8209;4H&;#8209;chromen-4-ones endowed with dual DNA-PK/PI3&;#8209;K inhibitory activity. J. Med. Chem., 2013, 56, 6386&;#8722;6401.
39.Bedeschi, A.; Zarini, F.; Cabri, W.; Candiani, I.; Penco, S.; Capolongo, L.; Ciomei, M.; Farao, M.; Grandi, M. Synthesis and antitumor activity of a new class of water soluble camptothecin derivatives. Bioorg. Med. Chem. Lett., 1996, 6,671-674.
40.Wan, S.; Sun, Y.; Qi, X.; Tan, F. Improved bioavailability of poorly water-soluble drug curcumin in cellulose acetate solid dispersion. AAPS PharmSciTech, 2012, 13, 159-166.
41.Ple, P. A.; Green, T. P.; Hennequin, L. F.; Gurwen, J.; Fennell, M.; Allen, J.; Costello, G. Discovery of a new class of anilinoquinazoline inhibitor with high affinity and specificity for the tyrosine kinase domain of c-Src. J. Med. Chem. 2004, 47, 871–887.
42.Tseng, C.-H.; Tzeng, C.-C.; Chiu, C.-C.; Yang, C.-L.; Lu, P.-J; Chou, C.-K.; Liu, C.-Y.; Chen, Y.-L. Synthesis and antiproliferrative evaluation of 9-methoxy-6-(piperazin-1-yl)-11H-indeno[1,2-c]quino- line-11-one derivatives. Part 4. Med. Chem. Commun., 2014, 5, 937-948.
43.Kraus, G. A.; Ridgeway, J. Total synthesis of coriandrin. J. Org. Chem., 1994, 59, 4735-4737.
44.Viswanathan, C. L.; Chaudhari, A. S. Synthesis and evaluation of uterine relaxant activity for a novel series of substituted p-hydroxy- phenyllethanolamines. Bioorg. Med. Chem., 2006, 14, 6581-6585.
45.Gronowitz, S.; Timari, G. A new method for the synthesis of 4-oxo-4,5-dihydrofuro[3,2-c]quinoline. J. Heterocyclic Chem., 1990, 1159-1160.
46.Shen, Y.-D.; Tian, Y.-X.; Bu, X.-Z.; Gu, L.-Q. Natural tanshinone-like heterocyclic-fused ortho-quinones from regioselective Diels–Alder reaction: synthesis and cytotoxicity evaluation. Eur. J. Med. Chem., 2009, 44, 3915-3921.